EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy

Hailei Du iD, Tong Lang iD, Xiaoxue Zha iD, Chao Qu iD, Ling Chen iD, Shihua Yao iD, Xing Feng iD, Zhaohui Jin iD

Proceedings of the National Academy of Sciences · 18.08.2026 · 123 (33)

DOI: 10.1073/pnas.2535328123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.08.2026. Verfasst von Hailei Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carnitine, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy resistance remains a major barrier to achieving sustained patient improvement in non–small cell lung cancer (NSCLCs). Here, through integrating CODEX, metabolomics, CyTOF, ATAC-seq, and single-cell spatial transcriptomics from NSCLC tumors, we uncover an unrecognized role of ALDH9A1 in promoting resistance to anti-PD-1 therapy. In immunocompetent, but not immunocompromised mouse models, loss of ALDH9A1 markedly restrains tumor growth. This effect is accompanied by increased maturation of tertiary lymphoid structures and reduced accumulation of protumorigenic MDSCs within tumor immune microenvironment. Mechanistically, ALDH9A1-driven carnitine production elevates acetyl-CoA levels, remodels chromatin accessibility, and activates Il1b superenhancers in tumor cells, thereby promoting MDSC polarization and CD8 + T cell exhaustion. In vivo, genetic or pharmacological inhibition of ALDH9A1, or antibody-mediated IL-1β neutralization, suppresses tumor progression and restores sensitivity to anti-PD-1 therapy. IL-1β further activates NF-κB and upregulates ALDH9A1, establishing a feedback ALDH9A1-IL-1β loop. Importantly, the ALDH9A1/IL-1β axis is frequently hyperactivated in NSCLC patients and correlates with inferior responses to anti-PD-1 immunotherapy. Together, this study reveals a previously unappreciated NSCLC-specific immunoregulatory pathway and identifies ALDH9A1 as a promising therapeutic target for improving immunotherapy efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarnitineDrug Resistance, NeoplasmAnimalsHumansMiceImmunotherapySignal TransductionMultiomicsCell Line, TumorTumor MicroenvironmentSingle-Cell AnalysisInterleukin-1beta

Stichwörter der Autor:innen

ALDH9A1IL-1βMDSCscarnitine metabolismsuperenhancer

Substanzen

CarnitineInterleukin-1beta

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
  • Department of Respiratory and Critical Care Medicine, Weifang Second People's Hospital, Weifang 261041, Shandong, China.
  • Department of Intensive Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031,…
  • Department of Intensive Care Medicine, Anhui Provincial Cancer Hospital, Hefei 230031, Anhui, China.
  • Department of Interventional Therapy, The First Hospital of Jilin University, Changchun 130012, Jilin, China.
  • Department of Public Laboratory Platform, The First Hospital of Jilin University, Changchun 130012, Jilin, China.

ORCID-Profile: Hailei Du, Tong Lang, Xiaoxue Zha, Chao Qu, Ling Chen, Shihua Yao, Xing Feng, Zhaohui Jin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Du, H., Lang, T., Zha, X., Qu, C., Chen, L., Yao, S., Feng, X., & Jin, Z. (2026). Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences, 123(33). https://doi.org/10.1073/pnas.2535328123

Vancouver

Du H, Lang T, Zha X, Qu C, Chen L, Yao S, et al. Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proceedings of the National Academy of Sciences. 2026;123(33). doi:10.1073/pnas.2535328123

BibTeX
@article{Du2026,
  author = {Du, Hailei and Lang, Tong and Zha, Xiaoxue and Qu, Chao and Chen, Ling and Yao, Shihua and Feng, Xing and Jin, Zhaohui},
  title = {Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {33},
  doi = {10.1073/pnas.2535328123}
}
Kostenlos starten →